Reply from the Authors of Eligibility for the Shorter MDR-TB Regimen: Ambiguities in the WHO Recommendations
Publisher
American Thoracic SocietyPubMed ID
28715258Language
enDescription
We regret that this article is behind a paywall.ISSN
1535-4970ae974a485f413a2113503eed53cd6c53
10.1164/rccm.201705-0988LE
Scopus Count
Collections
Related articles
- Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
- Authors: van Leth F, Günther G, Hoffmann H, Lange C, European MDR-TB Database Collaboration.
- Issue date: 2017 Dec 1
- Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
- Authors: Barry PM, Lowenthal P, True L, Henry L, Schack G, Wendorf K, Flood J, Shah N
- Issue date: 2017 Dec 1
- Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.
- Authors: Munoz-Torrico M, Salazar MA, Millán MJM, Martínez Orozco JA, Narvaez Diaz LA, Segura Del Pilar M, Visca D, D'Ambrosio L, Centis R, Migliori GB
- Issue date: 2018 Mar
- Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.
- Authors: Lange C, Duarte R, Fréchet-Jachym M, Guenther G, Guglielmetti L, Olaru ID, Oliveira O, Rumetshofer R, Veziris N, van Leth F, European MDR-TB database collaboration *.
- Issue date: 2016 Oct 15
- Effect of the short-course regimen on the global epidemic of multidrug-resistant tuberculosis.
- Authors: Sotgiu G, Migliori GB
- Issue date: 2017 Mar